OVERACTIVE BLADDER by Yordanov Delyan & Yordanova Lilyna
WORLD SCIENCE                                                                                                                          ISSN 2413-1032 
 
RS Global                                                                                                           № 4(56), Vol.1, April 2020 15 
 
OVERACTIVE BLADDER 
 
Yordanov Delyan,  
Dr., MD, Specialist Obstetrics and Gynecology, UMBAL "Deva Maria", Burgas 
Yordanova Lilyna,  
Dr., MD, Specialist Obstetrics and Gynecology, Bulgaria, Rousse, Kanev University Hospital 
 
DOI: https://doi.org/10.31435/rsglobal_ws/30042020/7018 
 
ARTICLE INFO 
Received: 14 February 2020 
Accepted: 10 April 2020 
Published: 30 April 2020 
 
ABSTRACT 
In recent years, there has been a steady increase in patients visiting a 
specialist for what is known as overactive bladder syndrome. Due to 
the extremely negative impact of the disease on patients' quality of life, 
timely diagnosis and adequate treatment choices are of the utmost 
importance. The guidelines presented include a description of the 
etiology and pathogenesis, basic principles of diagnosis, and current 
methods of treatment for this category of patients. 
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Introduction. Overactive bladder (OAB) is a widespread syndrome. According to the 
International Continence Society (ICS), 17% of Europe's adults have symptoms of OAB (Wein A.J., 
Rovner E.S., 2002). It should be noted that OAB without urinary incontinence (OAB-dry) is observed 
in 7.6% of women, and OAB in combination with urgency incontinence (OAB-wet) - in 9.3%. There 
is currently a tendency to increase the incidence of OAB and urinary incontinence in women at age 65 
and older. OAB is generally more frequent in women after 44 years (Stewart W.F., Van Rooyen, 
2003). There is no clear data on the spread of OAB in Bulgaria, but it is generally accepted that it is 
similar to that in European countries. 
Despite the fact that OAB is diagnosed more often in the elderly, its symptoms are also found 
in other age groups. Most patients are over 40 years of age. On the other hand, in men over 60 years 
there is a clear tendency to increase the incidence of the disease, and in women, on the contrary, 
decrease. Thus, OAB is a fairly common clinical syndrome that occurs in different age groups and 
leads to physical and social maladaptation. 
Discussion. It is well established that neurogenic and non-neurogenic factors are the basis for 
the development of OAB. Neurogenic disorders occur at the level of the supra-spinal centers of the 
nervous system and spinal cord pathways, and non-neurogenic disorders occur due to age-related 
changes in detrusor, intravesical obstruction, and anatomical changes in urethral and bladder position. 
There are currently 3 main theories about OAB. 
o Decreased central inhibitory effect on urination reflex. For example, as a result of a 
disorder of the blood supply to the brain (stroke); 
o Damage to axonal pathways and loss of peripheral inhibitory effects in spinal cord injury or 
multiple sclerosis; 
o Identification of neurotransmission processes in reflex junctions leads to detrusive 
hyperactivity corresponding to sphincter insufficiency and insufficient suppression of urinary reflex 
due to a decrease in volitional control of the act of urination (non-inhibitory neurogenic bladder). 
The spontaneous generation of action potential is quite limited in the bladder muscle, but with its 
partial denervation, the action potential can be transmitted from cell to cell, causing microcontraction in 
the smooth muscle cells of the detrusor, leading to increased bladder pressure and stimulation. of afferent 
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detrusor receptors. The trigger can also be damage to the inhibitory pathways in the central nervous 
system, sensitization of peripheral afferent nerve endings and denervation due to age-related changes or 
peripheral neuropathy in diabetes mellitus, ischemia of bladder smooth muscle cells. 
There are many risk factors for OAB, the most common of which are age, smoking, obesity, 
consumption of carbonated and caffeinated beverages, reduced consumption of vegetables, fruits and 
bread, increased consumption of beef, sugar (Zhang W., 2006; Gormley E.A., Lightner D.J., 2015). 
Urinary tract infection and overactive bladder 
Urges and urgent urinary incontinence often occur in the presence of urinary infection. 
Speaking of OAB, we should automatically exclude the presence of urinary tract infection. The urgent 
symptoms of cystitis cannot be regarded as OAB, they are symptomatic urge incontinence or 
symptomatic urgency caused by inflammation of the bladder mucosa. 
There is evidence that chronic inflammatory diseases of the bladder lie in the pathogenesis of 
OAB. The first step may be the loss of mucosal glycosaminoglycans of the mucosal layer, with 
subsequent disruption of bladder function, manifested by increased contractility of the detrusor 
(Damiano R., Cicione A., 2011). In the presence of recurrent infectious and inflammatory processes, 
the biologically active substances involved in the inflammatory reaction act on certain receptors, 
thereby contributing to the development of pathological hypersensitivity of the bladder due to C-fiber 
irritation (Siracusano S., 2009, Cucchi, S., Cucchi, S., Cucchi, 2009). 
History taking 
A detailed medical history is needed: data for conservative, drug and / or surgical treatment to 
determine their efficacy and side effects. 
Particular attention should be paid to the patient's age at the time of onset of symptoms, the 
presence of bowel disorders, sexual function and the nervous system. 
It is necessary to clarify the family history, obstetric and gynecological history, as well as the 
presence of brain and spinal cord injuries, the presence of symptoms of neurological diseases 
(dizziness, tinnitus, impaired coordination), which may be accompanied by symptoms of OAB. It is 
important to understand what medicines the patient is taking for other ailments - whether these 
medicines contribute to urinary incontinence. 
Laboratory diagnostics: Urinalysis 
The diagnosis of OAB involves two stages. In the first stage, the exclusion of other diseases 
that occur with urgent urination is performed. In the second stage, the type of the OAB is determined. 
The initial examination of a patient with suspected OAB should include a urinalysis to exclude acute 
and chronic bladder and urethral disorders. Bladder hypersensitivity to inflammation of the lower 
urinary tract may be a cause of OAB-specific complaints. 
Laboratory diagnostics: blood tests 
The standard biochemical blood test for the determination of creatinine and urea levels has 
important diagnostic value for assessing the condition of the urinary system. Blood glucose is also 
important. Elevated glucose levels indicate the possible presence of diabetes mellitus, which is 
accompanied by polyuria, leading to frequent urination during the day and night. 
Menopausal women often have a decrease in blood estrogen. Itching and burning in the 
genitals with hypoestrogenemia are not uncommonly accompanied by frequent urination, which may 
be mistaken for hyperactivity. However, sex hormone determination is not required in routine practice. 
Gynecological examination 
Gynecological examination of the vagina and cervix is required in women with suspected 
OAB. In this case, attention should be paid to the pelvic floor muscles, their tone, the anatomical 
position of the anterior and posterior walls of the vagina and uterus, and their ability to contract, which 
may also be the cause of OAB. A cough test is also performed to detect involuntary detrusor 
contractions caused by increased intra-abdominal pressure or accompanying urinary incontinence. 
Genital prolapse is a common cause of urinary disorders. Prolapse of the anterior wall of the vagina 
or uterus can lead to intravesical obstruction and urge symptoms. Very often, the prolapse of the vaginal 
walls, especially the anterior wall, causes inflammation of the bladder, which contributes to the appearance 
of symptoms of overactivity. Pelvic disorders, including pelvic descent and prolapse, as well as urinary 
incontinence, are disabling conditions that lead to surgical treatment in 1 in 9 women (Hubchev, G., 2017) 
Neurological examination 
In the presence of a neurological disease that may be the cause of the symptoms of the lower 
urinary tract, neurogenic OAB should be discussed. 
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Indications for Cystoscopy 
Endoscopic examination of the lower urinary tract is recommended in the following cases: 
• another pathology, such as hаematuria, was detected during the initial examination; 
• in the presence of pain or discomfort in the bladder - in patients with OAB, endoscopy can 
reveal an intravesical formation (stones, tumors), which can cause dysuria; 
• exclusion of extraurethral urinary incontinence or stress urinary incontinence, if necessary. 
Urethrocystoscopy examines the urethra and bladder for organic diseases, lesions and 
concrements. The response of urethral sphincter mechanisms and detrusor in response to bladder 
filling is evaluated. In women with stress incontinence, the bladder neck dilates when the bladder is 
filled, during straining and coughing, while at the compression command, the reaction is slow or 
absent. (G. Hubchev, 2017) 
Ultrasound indications and its characteristics 
Visualization of the lower urinary tract and pelvic organs is recommended in cases where 
concomitant pathology in this area is suspected during the initial examination. The initial stage may be 
ultrasound or X-ray examination. 
The determination of residual urine is recommended by ICS and is a routine screening test for 
all patients with urinary incontinence. The most commonly practiced is abdominal ultrasound. 
Urodynamic studies allow assessment of the condition of the lower urinary tract and formulate 
an additional plan for examination and treatment of the patient. 
Non-invasive tests include all urodynamic tests performed without the introduction of 
catheters or sensors (uroflowmetry, determination of residual urine volume). 
Invasive urodynamic testing (cystometry) is the standard for diagnosing the detrusor 
hyperactivity. According to cystometry data, the filling account for: increase in the sensitivity of the 
bladder, decrease in its elasticity and values of the so-called compliance (the ratio of the change in 
bladder volume to detrusor pressure). 
Treatment 
Behavioral therapy in the treatment of OAB is aimed at forming a new model of urination or 
restoration of the previous one, in which this process becomes controlled by the patient again 
(Ahlberg J., 2002). 
• Correction of fluid intake regime 
• Bladder training, exercise and biofeedback therapy 
• Medication treatment 
Antimuscarinic preparations (m-anticholinergic drugs) are currently the basis of treatment for 
OAB and urgent urinary incontinence. (Hubchev G., 2020). They differ in their pharmacological 
characteristics, for example, affinity for muscarinic acetylcholine receptors and other forms of action, 
in their pharmacokinetic properties, for example, lipid solubility, half-life. 
Oxybutynin; Tolterodine; Trospium chloride; Solifenacin; β-3-Adrenomimetics - Mirabegron; 
Vasopressin analogues - Desmopressin 
• Intravesical injections of botulinum toxin type A 
Intravesical administration of botulinum toxin type A at a dose of 100 units is a common method of 
treating OAB syndrome with persistent or refractory to m-anticholinergic therapy in women with urinary 
incontinence. In clinical studies, a single intravesical injection of botulinum toxin type A was shown to be 
more effective than the placebo effect, reducing the severity of urge incontinence symptoms, improving the 
patient's quality of life for 12 months (Vij M., Drake MJ, 2015 ). However, treatment is repeated on every 4-8 
months. There is no evidence of a decrease in the efficacy of type A botulinum toxin after repeated injection. 
• Neuromodulation 
The main difference between neuromodulation and other stimulation methods is the following: 
the effect manifests itself on nerve roots or peripheral nerves (in the case of tibial stimulation). 
• Urinary bladder augmentation and urine derivation 
Augmentation cystoplasty can only be offered to patients with refractory detrusor 
hyperactivity and urinary incontinence in case of unsuccessful conservative treatment, botulinum toxin 
injection and sacral electrical stimulation. The main indication for surgical treatment is a significant 
reduction in the anatomical capacity of the bladder. Patients who are offered cystoplasty augmentation 
or urinary derivation should be advised of the high risk of periodic bladder self-catheterization as well 
as of early and late complications and of a slightly increased risk of bowel cancer. 
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Conclusions. Modern urogynecology is aimed at providing high quality of life for patients. In 
this regard, particular attention is paid to the treatment of those uro-gynecological conditions that 
directly impair women's quality of life. OAB is a syndrome consisting of many symptoms (urgency, 
urge incontinence, frequent urination and nocturia). 
• Only urgency is a mandatory symptom of OAB. In order to be diagnosed, the specialist must 
rule out all other possible reasons for explaining the patient's complaints. 
• Urodynamic testing should be performed in situations where behavioral therapy and first-line 
treatment do not help. 
• Cystoscopy is indicated for women who complain of hematuria or painful urination. 
• Limiting your coffee or tea intake can very often eliminate or reduce your symptoms of OAB. 
• M-anticholinergics - first-line medicines for the treatment of OAB and urinary incontinence. 
• If the prescribed m-anticholinergic drug does not have sufficient therapeutic effect, another 
m-anticholinergic antagonist can be used and the dose increased to its maximum. 
• β-3-Adrenomimetic mirabegron may be prescribed to patients who have pronounced side effects 
from the use of m-anticholinergics, as well as to those patients who are not helped by m-anticholinergics. 
• Dose duplication of m-anticholinergics is acceptable in women with neurogenic urinary disorders. 
• Botulinum toxin for intravesical administration should be used in patients refractory to oral 
medicines. A dose of 100 units does not lead to a significant risk of urinary retention, and bladder 
infection is the most common side effect. 
• Augmentation of the bladder or the creation of a bowel reservoir is indicated in situations of 
dramatic reduction of the anatomical capacity of the bladder and total urinary incontinence. 
 
Fig. 1. An algorithm for the diagnosis and treatment of overactive bladder 
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